

1 State of Arkansas
2 83rd General Assembly
3 Regular Session, 2001

HCR 1031

4
5 By: Representative Trammell
6
7

8 **HOUSE CONCURRENT RESOLUTION**

9 URGING THE PHARMACEUTICAL MANUFACTURERS TO WORK
10 WITH THE AREA AGENCIES ON AGING TO PROVIDE
11 OUTREACH AND EDUCATION SERVICES TO ENCOURAGE
12 APPROPRIATE AND MORE COMPLETE UTILIZATION OF THE
13 MANUFACTURERS' "PATIENT ASSISTANCE PROGRAMS".
14

15 **Subtitle**

16 URGING PHARMACEUTICAL MANUFACTURERS TO
17 WORK WITH THE AREA AGENCIES ON AGING.
18
19

20 WHEREAS, many senior citizens in Arkansas must bear the costs of
21 pharmaceuticals more than any other component of health care, because they
22 lack appropriate prescription drug coverage; and
23

24 WHEREAS, the exclusion of a pharmaceutical component under Medicare
25 means that many patients over sixty-five (65) years of age must obtain
26 additional insurance in order to acquire medicines, or pay for them out of
27 their pocket; and
28

29 WHEREAS, the economic value of pharmaceuticals, realized through the
30 reductions in the use of more costly medical interventions, is substantial;
31 and
32

33 WHEREAS, in 2000 the pharmaceutical manufacturers of America donated
34 \$947 million dollars in free prescription drugs to the indigent needy in the
35 United States, through their "Patient Assistance Programs"; and
36

1 WHEREAS, the pharmaceutical industry continues to offer prescription
2 drugs at no cost to the needy citizens of Arkansas, but frequently the
3 logistics of the procurement process is unclear; and
4

5 WHEREAS, the Area Agencies on Aging serve as the primary communication
6 and information resource for senior citizens in Arkansas;
7

8 NOW THEREFORE,

9 BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE EIGHTY-THIRD GENERAL
10 ASSEMBLY OF THE STATE OF ARKANSAS, THE SENATE CONCURRING THEREIN:
11

12 That the General Assembly urges the pharmaceutical manufacturers to
13 work with the Area Agencies on Aging to provide outreach and education
14 services to encourage appropriate and more complete utilization of the
15 manufacturers' "Patient Assistance Programs".
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36